ECSP22020678A - Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares - Google Patents

Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares

Info

Publication number
ECSP22020678A
ECSP22020678A ECSENADI202220678A ECDI202220678A ECSP22020678A EC SP22020678 A ECSP22020678 A EC SP22020678A EC SENADI202220678 A ECSENADI202220678 A EC SENADI202220678A EC DI202220678 A ECDI202220678 A EC DI202220678A EC SP22020678 A ECSP22020678 A EC SP22020678A
Authority
EC
Ecuador
Prior art keywords
nrp1a
antibodies
eye diseases
treat eye
treat
Prior art date
Application number
ECSENADI202220678A
Other languages
English (en)
Inventor
Leo Thomas
Sarah Low
Juergen Prestle
Fei Han
Yining Huang
Nina Zippel
Pankaj Gupta
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2020/076685 external-priority patent/WO2021058636A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22020678A publication Critical patent/ECSP22020678A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de estos que actúan sobre el domino A de Neuropilina-1 (Nrp1A). Más específicamente, se divulgan anticuerpos anti-Nrp1A y métodos de uso para el tratamiento de varias enfermedades o trastornos.
ECSENADI202220678A 2019-09-24 2022-03-21 Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares ECSP22020678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19199099 2019-09-24
PCT/EP2020/076685 WO2021058636A1 (en) 2019-09-24 2020-09-24 Anti-nrp1a antibodies and their uses for treating eye or ocular diseases

Publications (1)

Publication Number Publication Date
ECSP22020678A true ECSP22020678A (es) 2022-04-29

Family

ID=68066567

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202220678A ECSP22020678A (es) 2019-09-24 2022-03-21 Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares

Country Status (2)

Country Link
AR (1) AR120038A1 (es)
EC (1) ECSP22020678A (es)

Also Published As

Publication number Publication date
AR120038A1 (es) 2022-01-26

Similar Documents

Publication Publication Date Title
MX2023015185A (es) Degradadores de proteinas y usos de los mismos.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2020000483A1 (es) Nuevos usos de derivados de piperidinil–indol.
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CO2021014768A2 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
CL2021000163A1 (es) Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139)
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
DOP2018000219A (es) Anticuerpos anti-factor bb del complemento y usos de estos
CL2020003008A1 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
DOP2024000117A (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
CL2021000930A1 (es) Piridazinas novedosas
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
MX2021009767A (es) Moleculas de union de fmcr y usos de las mismas.